Eterna Therapeutics Return on Equity

Eterna Therapeutics (ERNA) currently reports a ROE of -383.28%. That is below the Telecommunications sector average of 17.75%. Use the charts on this page to explore Eterna Therapeutics's ROE history and peer comparisons.

Eterna Therapeutics's ROE of -383.28% is lower than the Telecommunications sector average of 17.75%. That is roughly 2258.9% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Eterna Therapeutics's current -383.28% should be judged against Telecommunications norms (sector average: 17.75%) and against ERNA's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -383.28%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Telecommunications average is 17.75%. From there, open related valuation or income-statement pages for Eterna Therapeutics, and consider following ERNA for alerts when major investors trade the stock.

Eterna Therapeutics is classified in the Telecommunications sector. On ROE, it currently shows -383.28% versus a sector average near 17.75%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Telecommunications are usually more informative than comparing ERNA with unrelated industries.